Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease : Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease
Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease.Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 10. Okt. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 3, 2021, Last downloaded: ClinicalTrials.gov processed this data on October 18, 2023, Last updated: October 18, 2023 |
---|
Study ID: |
NCT04988282 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG007790260 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG007790260 | ||
003 | DE-627 | ||
005 | 20231018010346.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210804s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG007790260 | ||
035 | |a (UBBS_Klinische_Studien)NCT04988282 | ||
035 | |a (UBBS_Klinische_Studien)STERCOV-ILD | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease |b Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 3, 2021, Last downloaded: ClinicalTrials.gov processed this data on October 18, 2023, Last updated: October 18, 2023 | ||
520 | |a Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease.Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes. | ||
650 | 2 | |a COVID-19 | |
650 | 2 | |a Lung Diseases | |
650 | 2 | |a Lung Diseases, Interstitial | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 4 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 10. Okt. |
773 | 1 | 8 | |g year:2023 |g day:10 |g month:10 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04988282 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 10 |c 10 |